Manifesto for a European anxiety disorders research network.
Despite the size, burden and costs of anxiety disorders, many patients remain unrecognised, and the effectiveness of evidence-based interventions in routine clinical practice can be disappointing. The European College of Neuropsychopharmacology (ECNP) has established the ECNP Network Initiative (ECNP-NI) to help meet the goal of extending current understanding of the causes of central nervous system disorders, thereby contributing to improvements in clinical outcomes and reducing the associated societal burden. The Anxiety Disorders Research Network (ADRN) has been adopted within the ECNP-NI: this consensus statement summarises its overall aims and objectives.
Baldwin
David S
DS
Clinical Neuroscience Division, University of Southampton School of Medicine, Southampton, UK. dsb1@soton.ac.uk
Allgulander
Christer
C
Altamura
Alfredo Carlo
AC
Angst
Jules
J
Bandelow
Borwin
B
den Boer
Johan
J
Boyer
Patrice
P
Davies
Simon
S
Dell'osso
Bernardo
B
Eriksson
Elias
E
Fineberg
Naomi
N
Fredrikson
Mats
M
Herran
Andres
A
Maron
Eduard
E
Metspalu
Andres
A
Nutt
David
D
van der Wee
Nic
N
Vázquez-Barquero
Jose Luis
JL
Zohar
Joseph
J
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000150:complications / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D015897:Comorbidity; D032921:Consensus; D017281:Cost of Illness; D003469:Culture; D005060:Europe / Q000453:epidemiology; D006801:Humans; D015337:Multicenter Studies as Topic; D011634:Public Health; D012106:Research; D012109:Research Support as Topic; D017211:Treatment Failure
D014151:Anti-Anxiety Agents